Bold Vision.
Innovation at its best.

For almost 30 years, ProPhase has been relentlessly focused on enhancing wellness and improving health. Historically, we have been a diversified medical science and technology company that delivers breakthrough, clinically shown supplements, and OTC manufacturing. In 2020, we pivoted to build out state-of-the-art CLIA labs for COVID-19 diagnostic testing. In 2021, we acquired Nebula Genomics and formed ProPhase Precision Medicine. We are rapidly developing into a true diagnostics and genomics company that will leverage our CLIA laboratories for COVID-19 Testing, whole genome sequencing, and a wide variety of diagnostic testing. In 2022, we formed ProPhase BioPharma to license, develop and commercialize drugs and compounds with enormous potential. Our first licensing efforts included Equivir (OTC) and Equivir G (Rx), broad-based anti-viral compounds. We then licensed Linebacker 1 and 2, compounds that have multi-billion dollar potential as cancer co-therapies.